Polyrizon Ltd. (PLRZ) — SEC Filings

Polyrizon Ltd. (PLRZ) — 50 SEC filings. Latest: EFFECT (May 5, 2026). Includes 45 6-K, 2 20-F, 1 EFFECT.

View Polyrizon Ltd. on SEC EDGAR

Overview

Polyrizon Ltd. (PLRZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Apr 8, 2026: Polyrizon Ltd. filed a prospectus supplement (424B5) on April 8, 2026, related to its securities. The filing, with SEC Accession No. 0001213900-26-041507, provides updated information for investors. The company is located in Ra'anana, Israel.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 10 bullish, 2 bearish, 36 neutral, 2 mixed. The dominant filing sentiment for Polyrizon Ltd. is neutral.

Filing Type Overview

Polyrizon Ltd. (PLRZ) has filed 1 EFFECT, 45 6-K, 1 424B5, 1 20-F/A, 2 20-F with the SEC between Oct 2024 to May 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (50)

Polyrizon Ltd. SEC Filing History
DateFormDescriptionRisk
May 5, 2026EFFECTEFFECT Filing
May 4, 20266-K6-K Filing
Apr 8, 20266-K6-K Filing
Apr 8, 2026424B5Polyrizon Ltd. Files Prospectus Supplementlow
Mar 27, 202620-F/APolyrizon Amends 20-F, Affirms Controls Effective for 2025low
Mar 25, 202620-FPolyrizon Faces Funding Crunch, Regulatory Hurdles Amidst Deep Losseshigh
Dec 29, 20256-K6-K Filing
Dec 19, 20256-KPolyrizon seeks FDA designation for viral blockermedium
Dec 11, 20256-KPolyrizon Ltd. Advances Intranasal Naloxone Hydrogel Programmedium
Dec 8, 20256-KPolyrizon Ltd. Completes FDA Pre-Submission Meeting for Allergy Blockermedium
Dec 5, 20256-KPolyrizon Ltd. Prices $5M Direct Offering at Premiummedium
Dec 3, 20256-KPolyrizon Reports Positive Naloxone Hydrogel Mucoadhesion Resultsmedium
Dec 2, 20256-KPolyrizon Ltd. Upscales Nasal Spray Manufacturinglow
Nov 25, 20256-K6-K Filing
Nov 6, 20256-KPolyrizon Ltd. Reports Viral Blocking Breakthroughmedium
Oct 6, 20256-KPolyrizon Ltd. Reports Positive Pre-Clinical Results for PL-14medium
Sep 19, 20256-KPolyrizon Submits FDA Pre-Sub Package for Allergy Blockermedium
Sep 17, 20256-KPolyrizon Ltd. Files 6-K with Financialsmedium
Sep 4, 20256-KPolyrizon Ltd. Shareholders Approve All Proposalslow
Aug 14, 20256-KPolyrizon Ltd. Regains Nasdaq Listing Compliancelow

Risk Profile

Risk Assessment: Of PLRZ's 45 recent filings, 2 were flagged as high-risk, 28 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

  • Tomer Izraeli
  • Yehonatan Zalman Vinokur
  • Assaf Itzhaik
  • Liat Sidi
  • Omer Srugo
  • Liron Carmel
  • Dr. Michal Meir

Industry Context

Polyrizon Ltd. operates within a sector that requires robust financial reporting and internal controls, especially given its status as a foreign private issuer. The company's adherence to frameworks like COSO and compliance with SEC regulations are critical for maintaining investor confidence and market access.

Top Tags

press-release (8) · medical-devices (7) · drug-development (5) · shareholder-meeting (4) · corporate-governance (4) · clinical-trial (4) · drug-delivery (4) · regulatory-filing (3) · manufacturing (3) · compliance (3)

Key Numbers

Polyrizon Ltd. Key Metrics
MetricValueContext
Document Size (bytes)528829Size of the prospectus supplement file (ea0285368-424b5_polyrizon.htm)
Total fees paid to auditor in 2025$170,154Increased from $135,000 in 2024, reflecting audit, audit-related, and tax services.
Audit fees paid in 2025$100,000Consistent with audit fees paid in 2024, indicating stable core audit costs.
Ordinary Shares outstanding1,608,266As of December 31, 2025, representing the total number of shares.
Fiscal year ended2025The period covered by the amended annual report.
Filing date of 20-F/A2026-03-27Date the amendment was filed, correcting the original March 25, 2026 filing.
May Reverse Share Split Ratio1-for-250Effected on May 27, 2025, to consolidate ordinary shares and maintain Nasdaq listing.
November Reverse Share Split Ratio1-for-6Effected on November 28, 2025, further consolidating ordinary shares and maintaining Nasdaq listing.
Ordinary Shares Outstanding1,608,266As of December 31, 2025, after giving effect to both reverse splits.
Revenue from Product Candidate Sales$0Polyrizon has never generated any revenue from product candidate sales since its inception.
Offering Proceeds$5.0MCalculated from 552,269 shares at $9.00 per share, representing capital raised.
Share Price$9.00The price at which ordinary shares were sold in the registered direct offering.
Commission file number001-42375Identifies the company's SEC filings
SEC File Number001-42375Identifies Polyrizon Ltd.'s filings with the SEC.
Reverse Split Ratio1-for-250Indicates a significant consolidation of shares.

Related Companies

POLZ · XYLO

Frequently Asked Questions

What are the latest SEC filings for Polyrizon Ltd. (PLRZ)?

Polyrizon Ltd. has 50 recent SEC filings from Oct 2024 to May 2026, including 45 6-K, 2 20-F, 1 EFFECT. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of PLRZ filings?

Across 50 filings, the sentiment breakdown is: 10 bullish, 2 bearish, 36 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Polyrizon Ltd. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Polyrizon Ltd. (PLRZ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Polyrizon Ltd.?

Financial highlights for Polyrizon Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for PLRZ?

The investment thesis for PLRZ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Polyrizon Ltd.?

Key executives identified across Polyrizon Ltd.'s filings include Tomer Izraeli, Yehonatan Zalman Vinokur, Assaf Itzhaik, Liat Sidi, Omer Srugo and 2 others.

What are the main risk factors for Polyrizon Ltd. stock?

Of PLRZ's 45 assessed filings, 2 were flagged high-risk, 28 medium-risk, and 15 low-risk.

What are recent predictions and forward guidance from Polyrizon Ltd.?

Forward guidance and predictions for Polyrizon Ltd. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.